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Objectives: Surgical site infections (SSIs) after bypass procedures provoke major costs. The aim of this
prospective randomised trial was to assess if preoperative duplex vein mapping (DVM) reduces costs
generated by SSI.
Materials/methods: Patients undergoing primary infrainguinal bypass were randomised to DVM of the
ipsilateral greater saphenous vein (group A) or none (group B). Costs were calculated by the hospital’s
accounting department.
Results: From December 2009 to April 2011, 130 patients (65 each group) were enrolled. Both cohorts
were equal regarding demographics, risk factors and costs for primary bypass surgery, respectively. SSIs
were classiﬁed minor (A: n ¼ 13 vs. B: n ¼ 13, P ¼ n.s.) and major (A: n ¼ 1 vs. B: n ¼ 12, P ¼ .0154).
Preoperative DVM was the only signiﬁcant factor to prevent major SSI (P ¼ .011). Theatre costs for SSI: A:
537 V versus B 6553 V (P ¼ .16). Recovery room/intensive care unit (ICU) costs for SSI: A: 0 V versus B:
8016 V (P ¼ .22). Surgical ward costs for SSI: A: 2823 V versus B: 22 386 V (P ¼ .011). Costs for outpatient
visits due to SSI: A: 6265 V versus B: 12 831 V (P ¼ .67). Total costs of patients without SSI: 8177 V versus
major SSI: 10 963 V (P < .001).
Conclusion: DVMsigniﬁcantly reduces costs generatedby re-admission inpatients suffering frommajor SSI.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The main cause for increased costs in vascular surgery are
surgical site infections (SSIs), which may lead to extended hospital
stay, revision surgery, prolonged antibiotic treatment and increased
frequency of outpatient visits, respectively.1,2 SSIs are reported in
up to 43% after arterial reconstructions.3 In the 1980s, duplex vein
mapping (DVM) of the greater saphenous vein (GSV) was described
as a preoperative diagnostic adjunct to gain information about
anatomy and graft suitability in patients undergoing infrainguinal
bypass surgery.4,5 Further studies, all of which failed level-1
evidence, revealed that preoperative DVM of the ipsilateral GSV
alleviates vein harvest and may reduce SSI after bypass procedures
of the lower extremity.6e9 The aim of this prospective randomised
study was to evaluate if preoperative DVM is able to lower costs
signiﬁcantly by decreasing postoperative SSI.ery Annual Meeting, Chicago
European Society for Vascular
2011.
fax: þ43 662 4482 3207.
ciety for Vascular Surgery. PublisheMaterials and Methods
Patients
From December 2009 until April 2011, all patients who were
planned for primary infrainguinal bypass surgery underwent
evaluation for inclusion into this study. Patient datawere registered
prospectively in a designated vascular database at a university-
based tertiary care centre. Inclusion criteria were severe claudica-
tion and critical leg ischaemia10 as well as patients with popliteal
aneurysms. After written informed consent was provided, patients
were randomly allocated to two groups: group A patients under-
went preoperative DVM of the ipsilateral GSV and group B did not.
SSIs were classiﬁed according to the American College of Surgeon’s
National Surgical Quality Improvement Program (ACS-NSQIP) as
superﬁcial or deep.11 If oral antibiotics and topical treatment were
sufﬁcient, SSIs were regarded as minor. If intravenous antibiotic
therapy and/or redo surgery (debridement, etc.) were necessary,
SSIs were considered as major. In cases of primary ischaemic/
gangrenous lesions of the leg and/or postoperative SSI, samples for
bacterial culture were taken from the affected site. Primary studyd by Elsevier Ltd. All rights reserved.
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ative procedure, development of postoperative SSI, costs due to re-
admissions for SSI and costs due to outpatient visits for SSI,
respectively. Secondary ‘end’ points were bypass patency, limb
salvage and patient survival. Standard reporting guidelines were
applied.12 The study was approved by the Local Ethics Research
Committee. Preliminary data regarding clinical outcome in smaller
patient cohort were presented at the SVS in Chicago 2011.
Preoperative work-up, DVM and angiography
General work-up was identical for all patients and included
physical examination, cardiac testing, carotid duplex, pulmonary
evaluation upon the discretion of the attending cardiologist and
laboratory testing including screening for hepatitis and human
immunodeﬁciency virus (HIV).
Preoperative colour-ﬂow duplex scanning (DS) of the ipsilateral
GSV was performed in the vascular laboratory by three senior
surgeons (KL, EB and AU) using a 13-MHz probe (GE Healthcare
LOGIQ 7, Milwaukee, WI, USA) with the patient in supine position.
After measuring venous diameter at four different levels (proximal
and distal thigh, proximal and distal calf), using a high-thigh
tourniquet,13 the course of the GSV from ankle to groin and major
side branches were marked with indelible dye, which was not
antibacterial (e.g., gentian violet).
A vein >2.5 mm in diameter was considered as an adequate
conduit in duplex mapping. This corresponded to a 3-mm dis-
tended vein bypass graft.
In all patients, assessment of distal run-off vessels was per-
formed preoperatively.14 The procedure was planned according to
preoperative angiography.
Perioperative antibiotic regimen
Patients suffering from ischaemic ulceration or gangrene
received continuous antibiotic therapy adapted to antibiogram
from the day of admission. All other patients receive antibiotic
prophylaxis with cefazoline 2 g intravenously at the time of
induction and at 8 and 16 h postoperatively.
Bypass procedures (non-reversed, reversed, or in situ)
All patients underwent antiseptic prepping with coloured
Dodesept. After dissection of in- and outﬂow arteries, the ipsi-
lateral GSV was harvested via multiple vertical skin incisions with
intervening cutaneous bridges. Skin incisions were made with the
knife, dissection of deeper layers with a cautery. In the case of non-
reversed bypass, proximal valves were excised under direct vision,
remaining valves lysed by valvulotome (Mill’s type) introduced via
the distal end of the vein. In cases of in situ bypasses, valvulotomy
was performedwith a ﬂexible valvulotome (UreSil Tru-Incise, USA).
In all types of bypasses, a calliper was used for intra-operative
measurement of graft diameter and a ruler to measure graft
length. Wound closure was performed with running single layer
subcuticular sutures (Vicryl 3.0) and stainless skin staples.
The technique used for bypass surgery was at the discretion of
the surgeon. Technical details have been reported previously.15e17
Postoperative follow-up
Assessors (vascular surgeons) in the ward were not blinded to
the allocated treatment. After discharge clinical examination of the
study patients with measurement of ankle-brachial pressure index
(ABPI) and DS of the bypass were routinely carried out at 1, 3, 6 and
12 months postoperatively. In cases of SSI, patients were seen morefrequently in the outpatient department. The personnel in the
outpatient department (nursing staff and physician) had no access
to randomisation data and were therefore blinded to the allocated
treatment.Cost calculation
Costs were calculated by our hospital’s accounting department
as follows: costs for hospitalisation on the surgical ward (201.68
V/day, costs for DS included), recovery room (922.32 V/day),
intensive care unit (ICU) (1702.36 V/day), usage of operating room
(OR) (16.26 V/min) and outpatient visit (60.24 V/visit). Medication
during hospital stay was included into cost calculation. After
discharge, antibiotic treatment was excluded from cost calculation.
We distinguished four different types of costs: primary costs for
admission due to primary infrainguinal bypass procedure (surgical
ward, OR for primary bypass procedure, recovery room, ICU and
overall), secondary costs for re-admission due to SSI (surgical ward,
OR for revision surgery, recovery room, ICU and overall), costs for
outpatient visits and total costs (primary, secondary and outpatient
visits), respectively.Randomisation
Randomisation was carried out using sealed envelopes with the
allocation to DVM (group A) or not (group B).Statistical methods
No power analysis was done. Data were presented as
means  standard deviation (SD) and percentages. Fisher’s exact
and Pearson’s chi-square test were used for discrete variables, and
two-sided, unpaired Student’s t-test for continuously distributed
data. KaplaneMeier curves with 95% conﬁdence intervals (CIs)
were computed and compared using the log-rank test and Cox-F
test. Relative risks and 95% CIs were computed for selected cross-
tabulation tables. Computations for testing and estimation of
relative risks were done with MATHEMATICA 7.0. To detect inde-
pendent predictors of SSIs, in a ﬁrst step binary univariate logistic
regression analyses were done. Those variables in the model with
a P value less than 0.1 were included to build a multivariate model.
Odds ratios with 95% conﬁdence intervals are given in the multi-
variate model to get an impression of the magnitude of the effect.
All analyses were done by using Statistica 6.1 (StatSoft, Inc. 2004.
Statistica data analysis software system version 6.1), Statistical
Package for Social Sciences (SPSS) 10 (SPSS, Inc., 1999, Chicago, IL,
USA), and MATHEMATICA 7.1 (Wolfram Research, Inc., Mathema-
tica, Version 7.0, Champaign, IL 2008, USA). A P value less than 5%
was considered statistically signiﬁcant.Results
Patients
From December 2009 until April 2011, in 199 patients primary
infrainguinal bypass surgery was planned. As many as 135 of 199
(68%) patients met inclusion criteria (Table 1); 64/199 (32%)
patients were excluded for different reasons (Fig.1). Five of 135 (4%)
eligible patients refused randomisation; 130/199 (65%) patients
were randomly assigned to group A (with DVM, n ¼ 65) or B
(without DVM, n ¼ 65) (Fig. 1). Both groups were equal regarding
demographics, risk factors, surgical indication, preoperative ABPI
and distal run-off, respectively (Table 1).
Planned primary i
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Figure 1. Flow chart for patient exclusion and randomization for primary infrainguinal byp
preoperative duplex vein mapping; Group B: without preoperative duplex vein mapping.
Table 1
Demographics, risk factors and indication for operation in 130 randomized patients.
Group A
(n ¼ 65)
Group B
(n ¼ 65)
P value
Average age (years) 73.6 71.4 .24
Female (n/%) 20/30.8 22/33.8 .85
BMI 25.8 25.9 1.0
Hypertension (n/%) 54/83.1 55/84.6 1.0
Hyperlipidaemia (n/%) 33/50.8 35/53.8 .86
CAD (n/%) 33/50.8 35/53.8 .86
Diabetes (n/%) 33/50.8 30/46.2 .73
Smoking (n/%) 31/47.7 30/46.2 1.0
Renal impairment (n/%)* 18/27.7 15/23.1 .68
Rest pain (n/%) 9/13.8 11/16.9 .62
Ulceration/gangrene (n/%) 43/66.2 40/61.5 .64
Popliteal aneurysm (n/%) 5/7.8 10/15.4 .27
Preoperative ABPI .64  .28 .59  .34 .36
Distal run-off 1.5  .7 1.7  .8 .95
Group A: with duplex vein mapping; Group B: without duplex vein mapping; BMI:
body mass index (calculated as weight in kilograms divided by the square of height
in meters); CAD: coronary artery disease; CABG: coronary artery bypass graft;
* serum creatinine > 1.5 mg/dl and/or glomerular ﬁltration rate < 45 ml/min/m2;
ABPI: ankle-brachial pressure index.
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All mapped veins of group A patients were patent and usable for
bypass. Intra-operatively measured diameters of GSV did not differ
between group A and B patients at all levels (proximal thigh: P¼ .22,
distal thigh: P ¼ .36, proximal calf: P ¼ .09, distal calf: P ¼ .49).
Bypasses, bailout procedures and LOS
Femoroinfrapopliteal (distal anastomosis below the knee joint)
bypasses were performed signiﬁcantly more often than femo-
ropopliteal (distal anastomosis above the knee joint) bypasses in
both groups (P < .00001). Target vessels were distal popliteal artery
(group A: n ¼ 11, group B: n ¼ 15), tibioperoneal trunk (A: n ¼ 3, B:
n¼ 3), anterior tibial artery (A: n¼ 9, B: n¼ 8), posterior tibial artery
(A: n¼ 2, B: n¼ 5), peroneal artery (A: n¼ 9, B: n¼ 8), dorsalis pedis
artery (A: n ¼ 10, B: n ¼ 11) and medial plantar artery (A: n ¼ 3, B:
n ¼ 2). Translocated non-reversed bypass was the preferred tech-
nique followed by reversed and in situ bypass. Both groups were
equal regarding operative time, incisional length and overall bypass
length, respectively (Table 2). In group B, the surgical strategy had to
be changed in 6/65 (9.2%) patients always due to vein conduit issues
(insufﬁcient GSV diameter n¼ 4, sclerotic GSV n¼ 2) (Table 2). In 3/6
(50%) patients the accessory saphenous vein and in 2/6 (33.3%)nfrainguinal bypasses 
9-04/2011 
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Table 2
Bypass procedures and intra-operative ﬁndings in 130 randomized patients.
Group A (n ¼ 65) Group B (n ¼ 65) P value
Femoropopliteal BP (n/%) 18/27.7 14/21.5 .54
Femoroinfrapopliteal BP (n/%) 47/72.3 51/78.5 .54
Nonreversed BP (n/%) 46/70.8 50/76.9 .55
Reversed BP (n/%) 12/18.4 13/20.0 1.0
In situ bypass (n/%) 7/10.8 1/1.5 .061
Bridge graft18 (n/%) 0 1/1.5 1.0
Operative time (min) 156.7  61.5 153.3  52.4 .73
Incisional length (cm) 39.9  12.9 42.8  14.3 .41
Bypass length (cm) 35.1  9.9 35.3  10.9 .91
Operative plan changed 0 6 .027
Group A: with duplex vein mapping; Group B: without duplex vein mapping; BP:
bypass.
Table 4
Univariate binary logistic models to predict major surgical site infections.
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In one patient (16.7%), a bridge graft18 was performed with a short
patent segment of the GSV. Mean operative time and incisional
length in the latter group of patients were 152  40.9 min and
66  13.4 cm, which was not signiﬁcantly different with respect to
patients without change of surgical strategy.
Group A and B patients were equal regarding mean pre- and
postoperative LOS (6.4  4.7 days vs. 7.1  5.1 days; P ¼ .40; and
12.2  76.8 days vs. 13.7  9.9 days; P ¼ .30) and equal regarding
LOS in the recovery room and ICU for primary bypass surgery
(1.3  .7 days vs. 1.2  .4 days; P ¼ .45; and three days vs. 0 days;
P ¼ .24).
All patients received subcutaneous low-molecular-weight
heparin postoperatively until discharge. After discharge, 18
patients in group A and 21 patients in group B received oral anti-
coagulation (phenprocoumon or acenocoumarol, target Interna-
tional normalised ratio, INR, 2e3). There was no statistically
signiﬁcant difference between both groups regarding postoperative
anticoagulation.
Postoperative SSI and re-admissions due to SSI (Table 3)
In 39/130 randomised patients (30%), we observed 47 SSIs; 15/
47 SSIs (31.9%) were reported in group A and 32/47 SSIs (68.1%) in
group B; 14/65 patients (21.5%) in group A and 25/65 patients
(38.5%) in group B suffered SSI (relative risk [RR], .56; 95% conﬁ-
dence interval [CI], .32e.98; P ¼ .041). None of the SSIs led to
a prolonged LOS after the index procedure.
Major SSIs were signiﬁcantly less common in group A (RR, .08;
95% CI, .01e.62; P ¼ .0154). Minor SSIs were equally distributed
between both study groups.
Re-admissions due to SSI were seen signiﬁcantly less often in
group A patients (RR, .18; 95% CI, .04e.79; P¼ .022). In group A, two
patients (3.1%) were re-admitted because of SSI (one minor SSI forTable 3
Postoperative surgical site infections (SSI), readmissions, and deaths due to SSI in
130 randomized patients.
Group A
(n ¼ 65)
Group B
(n ¼ 65)
Relative risks
with 95% CI
P value
Minor SSI (n/%) 13/20.0 13/20.0 1 (.5e1.99) 1.0
Major SSI (n/%) 1/1.5 12/18.5 .08 (.01e.62) .0154
Readmissions due
to SSI (n/%)
2/3.1 11/16.9 .18 (.04e.79) .022
Mean LOS per
re-admission (days)
7  4.2 10.1  5.7 e .7
Deaths due to SSI 0/.0 2/3.1 0* - *
Group A: with duplex vein mapping; Group B: without duplex vein mapping; LOS:
length of hospital stay; CI: conﬁdence interval; * 95% CI and P value cannot be
computed.wound care due to poormedical attendance at home and onemajor
SSI for surgical revision with debridement). In group B, 11 patients
(16.9%) were re-admitted due to SSI (all major SSIs, six intravenous
antibiotic treatment and ﬁve surgical revision with debridement).
One group A patient with major SSI refused re-admission and was
managed conservatively over a period of 4 months until wound
complication was healed.
Mean duration of LOS at re-admission did not differ between
both groups (P ¼ .7), indicating a similar severity of SSI in both
groups. Two patients in group B died after re-admission due cardiac
failure related to septic complications following major SSI.
Predictors of major SSI
Preoperative DVM was the only signiﬁcant factor predicting the
development of postoperative major SSI (odds ratio, 14.59; 95% CI,
1.8e115; P ¼ .011) (Table 4).
Primary costs in 130 randomised patients
There was no signiﬁcant difference regarding mean surgical
ward costs for pre- (P ¼ .38) and postoperative LOS (P ¼ .86), OR
costs (P¼ .38), recovery room costs (P ¼ .12) and ICU costs (P ¼ .08),
respectively, between group A and B patients (Table 5).
Secondary costs
There was a signiﬁcant difference between group A and B
patients regarding mean secondary surgical ward costs (P ¼ .011)
and overall secondary costs due to re-admission for SSI (P ¼ .008)
(Table 6). Secondary costs for revision surgery, recovery room and
ICU were equal between group A and B patients suffering from SSI.
Costs for outpatient visits
Mean costs for outpatient visits were equal between group A
and B patients (496 V vs. 363 V; P ¼ .29). Mean costs for outpatient
visits in patients with SSI did not differ signiﬁcantly between group
A and B patients (448 V vs. 513 V; P ¼ .67).
Total costs for patients with major SSI
There was a signiﬁcant difference of mean total costs between
patients without SSI and patients suffering frommajor SSI (90V vs.
843 V; P < .001).Factors Odds ratio with 95% CI P value
Female gender .37 (.12e1.17) .089
Femoropopliteal BP 1.26 (.39e4.2) .89
Femoroinfrapoliteal BP 1.1 (.28e4.26) .89
In-situ BP .88(.1e7.7) .91
Distal run-off 1.47 (.71e3.0) .60
Diabetes .86 (.35e3.5) .86
Hypertension 1.65 (.41e6.6) .48
Hyperlipidaemia .93 (.3e2.95) .92
Smoking .47 (.14e1.61) .23
Renal impairment .74 (.21e2.59) .64
BMI 1.1 (.98e1.21) .13
CAD .45 (.13e1.55) .21
Fontaine IV (tissue loss) 1.59 (.50e5.04) .38
Anticoagulation .46 (.14e1.47) .19
Preoperative DVM* 14.5 (1.8e115) .011
BP: bypass; BMI: body mass index; CAD: coronary artery disease; DVM: duplex vein
mapping; CI: conﬁdence interval.
Table 7
Mean secondary costs for 6 Group B patients with intra-operative change of surgical
strategy compared to 124 patients without intra-operative change.
Intraoperative
change (n ¼ 6)
No intra-operative
change (n ¼ 124)
P value
Major SSI/% 3/50 10/8 .013
Minor SSI/% 2/33.3 24/19.4 .34
Readmissions due
to SSI/%
3/50 10/8 .013
Surgical ward costs 1109 V 150 V .0008
Operative costs 870 V 20 V .0006
Recovery room costs 769 V 0 V .0001
ICU costs 284 V 71 V .0021
Overall costs 3031 V 184 V .0008
SSI: surgical site infections; ICU: intensive care unit.
Table 5
Mean primary costs in 130 randomized patients undergoing infrainguinal bypass
surgery.
Group A (n ¼ 65) Group B (n ¼ 65) P value
Preoperative surgical ward costs 1288 V 1437 V .38
Operative costs 2548 V 2493 V .38
Recovery room costs 1234 V 1064 V .12
ICU costs 79 V 0 V .08
Postoperative surgical ward costs 2457 V 2771 V .86
Overall costs 7606 V 7764 V 1.0
Group A: with duplex vein mapping; Group B: without duplex vein mapping; ICU:
intensive care unit.
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change of surgical strategy
Patients with intra-operative change of surgical strategy and
patients without strategy change were equal regarding primary
costs for preoperative LOS (P ¼ 1.0), bypass surgery (P ¼ .40),
recovery room (P ¼ .87), ICU (P ¼ .69) and postoperative LOS
(P ¼ .93), respectively.
Secondary costs for surgical ward (P ¼ .0008), revision surgery
(P ¼ .0006), recovery room (P ¼ .0001) and ICU (P ¼ .0021) were
signiﬁcantly increased in patients with intra-operative change of
surgical strategy compared to patients without intra-operative
change (Table 7).Follow-up, bypass patency, limb salvage and survival
No patient was lost to follow-up. Mean follow-up time was
7.4  4.2 months and 7.3  4.4 months for group A and B patients
(P ¼ .83); 7/130 primary bypasses (5.4%) occluded. Two bypasses in
each group failed within 30 days (30-day secondary bypass patency
rates: 96.2%). Late bypass occlusions have been observed in one
group A patient (6 weeks postoperatively) and in two group B
patients (9 weeks and 10 weeks postoperatively), respectively. The
cause for early and late bypass occlusions could not be determined.
Six minor amputations in group A and ﬁve in group B had to be
performed during follow-up period. One diabetic patient in group A
without SSI and with patent bypass underwent below-knee major
amputation 6 months after bypass surgery because of progressive
gangrene of the foot (limb salvage rate 98.5%).
Thirty day survival rates were 100% in group A and 97% in
group B.Discussion
The study showed that major SSIs provoked signiﬁcantly
increased total costs in patients suffering from major SSI compared
to patients without SSI (P ¼ .001). Preoperative DVM and marking
of the ipsilateral GSV was the only independent predictor for
development of major wound complications after infrainguinal
bypass surgery, which conﬁrms the importance of DVM asTable 6
Mean secondary costs due to major surgical site infections.
Group A (n ¼ 2) Group B (n ¼ 11) P value
Surgical ward costs 1412 V 2035 V .011
Operative costs 269 V 596 V .16
Recovery room costs 0 V 419 V .16
ICU costs 0 V 309 V .15
Overall costs 1681 V 3360 V .008
Group A: with duplex vein mapping; Group B: without duplex vein mapping; ICU:
intensive care unit.a diagnostic tool prior to lower extremity revascularisation in
reducing secondary in-hospital costs signiﬁcantly. In-situ bypass
technique was nearly signiﬁcantly distributed between groups A
and B (Table 2) and may in part explain the ﬁndings of this study.
Postoperative wound complications as a major factor for
increased costs after lower extremity revascularisation are reported
in the literature but detailed cost analyses are rare.
Kent et al. reported additional mean costs per patient of 688 $
due to prolonged hospitalisation, rehospitalisation, re-operation,
rehabilitation and visiting nurse services caused by wound
complications after lower limb revascularisation.1 The authors
concluded that costs would have been higher in cases of major
wound complications, which was conﬁrmed by our study (mean
additional costs per patient due tomajor SSI: 1681V in group A and
3360 V in group B). In our study, SSI did not cause a prolonged
primary hospital stay, but the main difference of additional costs
between both study groups was due to secondary admission for
major SSI, whereas secondary costs for recovery room and ICU at
re-admission were equal. Rehabilitation costs and costs for visiting
nurse services were not part of our study. Costs for outpatient visits
in group B patients who suffered signiﬁcantly more major SSI were
not different from group A patients because patients suffering from
major SSI were re-admitted early for conservative or surgical
treatment.
Similar to our results, a Scandinavian prospective multicentre
observational study reported average costs attributable to SSI after
vascular surgery of 3320 V per patient.3 Included were costs for
additional days of hospitalisation, operating department fees for
reexploration and revision, visits to outpatient clinic, outpatient
nursing visit and rehabilitation.
Unexpectedly, all mapped veins of group A patients were usable
for bypass surgery, whereas in six group B patients (without
preoperative DVM) the surgical strategy had to be changed intra-
operatively due to vein conduit issues. This difference was statis-
tically signiﬁcant (P ¼ .027). On the other hand, the outcome of
patients undergoing intra-operative change of surgical strategywas
poor (three major SSIs, three re-admissions, two bypass occlusions
and one death due to cardiac failure after sepsis). Fifty percent of
these patients developed major wound complications. This could
be the result of the creation of extended undermined skin ﬂaps in
search of surgical alternatives to a poor quality ipsilateral GSV.
Interestingly, mean operative timewas not signiﬁcantly different to
patients without intra-operative strategy change. Overall incisional
length was considerably longer in patients with intra-operative
change of surgical strategy but did not reach statistical signiﬁ-
cance compared to patients without strategy change (P ¼ .07).
Regarding secondary costs, patients with intra-operative strategy
change caused signiﬁcantly increased expenses due to re-
admission for major SSI, revision operation, recovery room and
ICU compared to patients without strategy change (Table 7).
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support the application of DVM and marking prior to infrainguial
bypass procedure, some critical remarks have to be made.
No power analysis was made and the study was stopped after
observing that there were eleven more subjects with major SSI in
Group B compared to Group A. This stopping procedure is a limi-
tation of the study and the ﬁndings might be a random high
difference.
Up until now there are no precise duplex-based criteria
regarding which GSV is “acceptable or usable” for infrainguinal
bypass grafting. Our criteria (diameter > 2.5 mm, no signs of
thrombosis or sclerosis) for an acceptable and usable vein for
infrainguinal bypass grafting were based on the criteria described
in the literature.19,20 Critics may argue that a 100% GSV “usability
rate” in group A patients is not realistic and would have been lower
if additional diagnostic tools such as angioscopy would have been
used. On the other hand, we can report a 30-day patency rate of
96.2% and three bypass occlusions after a mean follow-up of 7.3
months in patients with preoperative DVM, which is within
accepted standards.
In addition to angioscopy to verify the usability of the GSV for
infrainguinal bypass procedures, some authors prefer endoscopi-
cally guided harvest of the GSV to reduce postoperative wound
complications.21e23 Neither angioscopy nor endoscopical vein
harvest were part or aim of our study and the latter technique did
not prove to cause a better outcome compared to preoperative DVM
regarding the prevention of wound complications after infrain-
guinal bypass surgery.21
Conclusion
In the case of major wound complications after primary
infrainguinal bypass surgery, the additional costs are signiﬁcant
and mainly caused by re-admission. Major SSIs after infrainguinal
bypass surgery can be prevented by preoperative DVM andmarking
of the ipsilateral GSV. Therefore, this technique should be a stan-
dard preoperative diagnostic adjunct for infrainguinal bypass
surgery. In the case of an intra-operative change of surgical strategy
during primary infrainguinal bypass surgery, the postoperative
outcome could be poor and secondary costs due to SSI signiﬁcant
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